SK BIOSCIENCE CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57,400 KRW | -0.17% |
|
0.00% | -20.28% |
| Mar. 28 | SK Bioscience Signs Deal with Sanofi for Five Vaccine Types | MT |
| Mar. 07 | SK Bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline | CI |
ETFs positioned on SK bioscience Co.,Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.57% | 2 M€ | -14.14% | ||
| 0.78% | 16 M€ | -8.49% | ||
| 0.04% | 15 M€ | +11.24% | ||
| 0.02% | 2,808 M€ | +5.90% | - | |
| 0.02% | 441 M€ | +3.02% | - | |
| 0.02% | 149 M€ | +0.92% | - | |
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | +1.11% | - | |
| 0.01% | 7 M€ | +1.95% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 34 M€ | +4.85% | - | |
| 0.00% | 302 M€ | +3.80% | - | |
| 0.00% | 39 M€ | +2.96% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 7 M€ | +0.11% | - |
SK Bioscience Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biological products. The Company's main products include vaccines such as SKYCellflu and Rotatech. The Company also sells infusion solutions. In addition, the Company engages in technology export business. The Company sells its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
57,400
KRW
Average target price
58,000
KRW
Spread / Average Target
+1.05%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.28% | 3.22B | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.27% | 29.48B | |
| +57.86% | 25.43B | |
| -17.69% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- A302440 Stock
- Funds and ETFs SK bioscience Co.,Ltd.
